TIMP1

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Retrieved on: 
Monday, November 13, 2023
Hepatology, Hyaluronic acid, Safety, Conditional sentence, ACE, ALT, AASLD, Physician, Disease, Risk, Artificial intelligence, Clinical trial, Liver disease, Cirrhosis, KPA, Collagen, Liver, TIMP1, HEPA, Fibrosis, Drug, Doctor of Philosophy, MASH, Patient, ELF, F4, Medical imaging, Pharmaceutical industry, Dietary supplement, F3

EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”; previously referred to as “NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced additional efficacy data for rencofilstat, its lead drug candidate.

Key Points: 
  • Dr. Mayo’s presentation indicated that 17 weeks of rencofilstat treatment was associated with significant reduction in liver stiffness (FibroScan®) in MASH subjects with advanced F3, an outcome suggesting reduction in hepatic fibro-inflammation.
  • Ongoing hepatic fibro-inflammation leads to progressive accumulation of collagen or fibrosis, increasing liver stiffness, and functional deterioration.
  • The predictive power of liver stiffness measurements on the course of disease is further enhanced when taken together with blood-based markers of liver disease.
  • Reduction in liver stiffness by rencofilstat likely indicates reduction in fibroinflammation, and reduction in risk for subsequent clinical outcome.

Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody

Retrieved on: 
Wednesday, September 28, 2022
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Therapy, IPF, Fibroblast, Safety, B cell, Cytokine, Fibrosis, MD, American Thoracic Society, Neoplasm, Antibody, Maintenance, NK, Patient, Program, Cancer, TGF, TIMP1, IL-6, Lung, Pharmacokinetics, Skin, ATS, Vaccine

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and oncology, today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.

Key Points: 
  • Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and oncology, today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.
  • The Phase 1 single and multiple ascending dose study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of LASN01 in healthy volunteers.
  • The initiation of this Phase 1 trial and the LASN01 clinical program is based in part on pre-clinical data reported at the American Thoracic Society (ATS) Annual Meeting 2022.
  • Inhibition of IL-11 signaling also showed a significant anti-fibrotic effect in the lung and skin in animal models of fibrosis.

Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis at Keystone Symposia Conference

Retrieved on: 
Wednesday, June 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Antibody, Doctor of Philosophy, Fibrosis, Skin, Therapy, TIMP1, Cytokine, Degenerative disease, American Thoracic Society, Cancer, Bronchoalveolar lavage, IL-6, BAL, B cell, Lung, Fibroblast, STAT3, ERK, IPF, Patient, Idiopathic pulmonary fibrosis, Conference, ATS, Vaccine, Keystone

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado.

Key Points: 
  • Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado.
  • The data build upon the results in models of lung fibrosis recently presented at the American Thoracic Society (ATS) conference in May.
  • IL-11R blockade provides a novel therapeutic approach to idiopathic pulmonary fibrosis (IPF) and potentially other grievous fibrotic diseases involving fibrosis in skin such as systemic sclerosis, said David King, PhD, Chief Scientific Officer of Lassen.
  • Lassen Therapeutics develops breakthrough antibodies as potential treatments for fibrosis, rare diseases, and oncology.

Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting

Retrieved on: 
Tuesday, May 17, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Annual general meeting, American Thoracic Society, Doctor of Philosophy, Antibody, Therapy, Cytokine, Degenerative disease, TIMP1, Fibrosis, Primate, ATS, Toxicity, Biomarker, TGF, IL-6, Idiopathic pulmonary fibrosis, B cell, IPF, Cancer, Vaccine, Medical imaging

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, is presenting new preclinical data on LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody, today at the American Thoracic Society (ATS) Annual Meeting being held in San Francisco.

Key Points: 
  • Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, is presenting new preclinical data on LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody, today at the American Thoracic Society (ATS) Annual Meeting being held in San Francisco.
  • The data demonstrate that LASN01 is a potent inhibitor of IL-11 signaling and shows anti-fibrotic effects in multiple preclinical models.
  • IL-11 is a key biological mediator in many fibrotic diseases including idiopathic pulmonary fibrosis (IPF), said David King, PhD, Chief Scientific Officer of Lassen.
  • Combined, these data strongly indicate the potential of LASN01 as a novel therapeutic approach for treatment of IPF and other fibrosing interstitial lung diseases.